- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01016093
Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients
July 25, 2011 updated by: Tehran University of Medical Sciences
Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients: A Prospective Pilot Study
This is prospective randomized, double blind study designed to evaluate the use of zoledronic acid in the prevention prevention of bone loss post allogenic BMT done for beta-thalassemia major patients.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of, 14114
- Hematology-Oncology & SCT Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed written informed consent.
- Patients must be 18 years old and over.
- Diagnosed with beta-thalassemia major
- Scheduled for allogenic bone marrow transplantation
- The date of randomization must be no more than 1 week after BMT.
- Patients must be accessible for follow-up.
- Life expectancy of at least 12 months from randomization.
Exclusion Criteria:
- Patients with any clinical or radiological evidence of existing fracture in the lumbar spine and/or total hip.
- Patients with a history of fracture with low-density or no associated trauma.
- Osteoporotic patients with T-score <= -2.5
- Previous treatment with a bisphosphonate.
- Patients with abnormal renal function as evidenced by either a serum creatinine determination 1.5 x or greater above the upper limit of normal or by a calculated creatinine clearance of 30 ml/minute or less.
- Pregnancy and lactation.
- Women of childbearing potential not on a medically recognized form of contraception.
- Subjects who, in the opinion of the investigator, are unlikely to cooperate fully during the study.
- Subjects participating simultaneously in studies with unapproved drugs, indications or treatment regimens.
- Known hypersensitivity to zoledronic acid or bisphosphonates.
- Patients with prior exposure to anabolic steroids, growth hormone, Parathyroid Hormone (PTH) or other drugs known to affect the skeleton (e.g., calcitonin, mithramycin, or gallium nitrate).
- Serious intercurrent illness
- History of metabolic bone diseases
- History of corticosteroid treatment for other causes
- History of antiepileptic drug treatment
- History or surgery at the lumbosacral spine, with or without implantable devices.
- Any disease of the spine that would preclude the proper acquisition of a lumbar spine DXA.
- Mental illness that precludes the patient from giving informed consent.
- Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.
- Recent (within 6 weeks) or planned dental or jaw surgery (e.g.. extraction, implants)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Patients in this arm received zoledronic acid.
|
Zoledronic acid 4 mg adjusted dose based on renal function IV 15-minute infusion every 3 months for a total of one year ( 4 doses ) beginning as soon as possible after randomization.
Other Names:
|
Placebo Comparator: Control
Patients in this arm received placebo as control group
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To describe the percent change in the lumbar spine (L1 to L4) BMD, as measured by dual energy X-ray absorptiometry, at 12 months in patients with beta-thalassemia major undergoing allogenic BMT randomized to zoledronic acid versus placebo.
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To describe the percent change in total hip BMD at 12 months in the two study arms.
Time Frame: 1 year
|
1 year
|
To compare the changes in bone turn over markers at 3, 6, and 12 months in the two treatment arms.
Time Frame: 1 year
|
1 year
|
To describe the incidence rate of all clinical fractures at 1 year in the two study arms.
Time Frame: 1 year
|
1 year
|
To describe the general safety of zoledronic acid.
Time Frame: 1 year
|
1 year
|
To describe the percent change in lumbar spine (L1 to L4) BMD and total hip BMD at 6 months when available.
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2009
Primary Completion (Anticipated)
November 1, 2011
Study Completion (Anticipated)
December 1, 2011
Study Registration Dates
First Submitted
November 17, 2009
First Submitted That Met QC Criteria
November 17, 2009
First Posted (Estimate)
November 18, 2009
Study Record Updates
Last Update Posted (Estimate)
July 26, 2011
Last Update Submitted That Met QC Criteria
July 25, 2011
Last Verified
July 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HORCSCT-0601
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bone Marrow Transplantation
-
National Center for Complementary and Integrative...National Cancer Institute (NCI)CompletedStem Cell Transplantation | Bone Marrow TransplantationUnited States
-
GlaxoSmithKlineCompletedBone Marrow TransplantationUnited States
-
Massachusetts General HospitalCompleted
-
Wake Forest University Health SciencesOhio State University; University of Mississippi Medical CenterCompletedBone Marrow TransplantationUnited States
-
University of PittsburghRecruitingBone Marrow Transplantation | Solid Organ TransplantationUnited States
-
Hospital Israelita Albert EinsteinRecruitingImpact of Yoga and Gentle Massage Practices on Symptom Management in Patients Undergoing HSCT (Yoga)Bone Marrow Transplantation | Hematopoietic Stem Cell TransplantationBrazil
-
National Institute of Allergy and Infectious Diseases...RecruitingBone Marrow TransplantationUnited States
-
Ming-Yuan ChihCompleted
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedBone Marrow Transplantation
-
University of California, San FranciscoCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States